Literature DB >> 16755476

Risk factors for candidemia in pediatric patients with congenital heart disease.

Lucia Garcia-San Miguel1, Javier Cobo, Isabel Martos, Enrique Otheo, Alfonso Muriel, Vicente Pintado, Santiago Moreno.   

Abstract

OBJECTIVE: To identify the main risk factors for the acquisition of candidemia in children with congenital heart disease (CHD) in order to improve the clinical management of these patients.
DESIGN: A case-control study.
SETTING: A large tertiary-care referral center in Spain with a pediatric intensive care unit (PICU) to which more than 500 children with CHD are admitted annually. PATIENTS: All patients had CHD and were admitted to the PICU during 1995-2000. Case patients were defined as patients with candidemia, and control patients were defined as patients without candidemia.
RESULTS: Twenty-eight case patients and 47 control subjects were included in the study. Case patients were younger (mean age [+/-SD], 12.5+/-32.0 vs 38.0+/-48.0 months; P<.01) and had a longer median PICU stay (19 vs 4 days; P<.01), and a greater percentage of case patients previously had Candida species isolated from specimens other than blood (eg, bronchial aspirates, urine, or skin specimens) (39% vs 4%; P<.01). Severity of clinical condition, as measured by the Therapeutic Intervention Scoring System (TISS) 1 week after PICU admission (odds ratio, 1.15; 95% confidence interval, 1.05-1.26; P<.01), and receipt of antibiotic treatment for more than 5 days (odds ratio, 13.42; 95% confidence interval, 1.31-137.13; P=.03) were independently associated with the development of candidemia.
CONCLUSIONS: Patients with CHD who have a high TISS score 1 week after PICU admission and patients who have received prolonged antibiotic therapy should be considered at high risk for candidemia. Our results suggest that shorter courses of antibiotic therapy, routine surveillance culture for Candida species, and initiation of preemptive or empirical antifungal treatment could help in the clinical management of these patients.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16755476     DOI: 10.1086/505094

Source DB:  PubMed          Journal:  Infect Control Hosp Epidemiol        ISSN: 0899-823X            Impact factor:   3.254


  6 in total

1.  Canadian clinical practice guidelines for invasive candidiasis in adults.

Authors:  Eric J Bow; Gerald Evans; Jeff Fuller; Michel Laverdière; Coleman Rotstein; Robert Rennie; Stephen D Shafran; Don Sheppard; Sylvie Carle; Peter Phillips; Donald C Vinh
Journal:  Can J Infect Dis Med Microbiol       Date:  2010       Impact factor: 2.471

2.  Risk factors for candidemia in pediatric intensive care unit patients.

Authors:  Hasan Ağın; Ilker Devrim; Rana Işgüder; Utku Karaarslan; Esra Kanık; Ilker Günay; Miray Kışla; Sultan Aydın; Gamze Gülfidan
Journal:  Indian J Pediatr       Date:  2014-03-14       Impact factor: 1.967

3.  Fatal Postoperative Candida glabrata Septicemia in a Child with Congenital Heart Disease.

Authors:  Vasant Baradkar; Shripad Taklikar; Simit Kumar
Journal:  J Glob Infect Dis       Date:  2009-01

Review 4.  The effect of biomaterials and antifungals on biofilm formation by Candida species: a review.

Authors:  M Cuéllar-Cruz; A Vega-González; B Mendoza-Novelo; E López-Romero; E Ruiz-Baca; M A Quintanar-Escorza; J C Villagómez-Castro
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2012-05-12       Impact factor: 3.267

Review 5.  Candidemia in children after complex congenital heart defects surgery treated with caspofungin--our own experience and a review of literature.

Authors:  Radoslaw Jaworski; Ninela Irga; Ireneusz Haponiuk; Maciej Chojnicki; Elzbieta Arlukowicz; Mariusz Steffek; Mariusz Sroka; Katarzyna Gierat-Haponiuk; Jacek Juscinski; Lucyna Palkowska; Aneta Sendrowska; Wojciech Kosiak
Journal:  Med Sci Monit       Date:  2011-05

6.  Epidemiologic surveillance of nosocomial infections in a Pediatric Intensive Care Unit of a developing country.

Authors:  María R Becerra; José A Tantaleán; Víctor J Suárez; Margarita C Alvarado; Jorge L Candela; Flor C Urcia
Journal:  BMC Pediatr       Date:  2010-09-10       Impact factor: 2.125

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.